Cancer Channel
Topics
Medications
Quicklinks
Related Channels

Revlimid Dosage

Recommended Revlimid Dosage for Mantle Cell Lymphoma

The usual recommended dose for the treatment of mantle cell lymphoma (MCL) is 25 mg a day for 21 days, followed by 7 days of no medication. This 28-day cycle is then repeated. People with kidney disease will normally be started on a lower amount.
 
People who experience potentially dangerous Revlimid side effects, such as low blood cell counts, may need to temporarily stop taking this drug. It may be restarted, usually at a lower dose, when the side effects improve.
 

General Information on Taking Revlimid

Some considerations to keep in mind during treatment with Revlimid include the following:
 
  • This medication comes in the form of a capsule. It is usually taken by mouth once a day.
     
  • You should take your Revlimid dose with a large glass of water, with or without food. If it seems to bother your stomach, try taking it with food.
     
  • Revlimid capsules should be swallowed whole; do not open, break, or chew them.
     
  • Try to take your dose at the same time each day to keep an even level of the medication in your bloodstream.
     
  • Treatment is usually continued for as long as it is working and not causing unacceptable side effects.
     
  • For the medication to work properly, it must be taken as prescribed. Do not stop taking this medicine without first talking to your healthcare provider.
     
  • If you are unsure about anything related to your dosage or Revlimid dosing in general, please talk to your healthcare provider or pharmacist.
5 Easy Tips to Manage Visitors During Cancer Treatment

Revlimid Medication Information

Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2017 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.